Literature DB >> 371627

An antineuronal antibody cross-reacting with erythrocytes and lymphocytes in systemic lupus erythematosus.

B Bresnihan, M Oliver, B Williams, G R Hughes.   

Abstract

An antibody with erythrocyte and lymphocyte activity, present in the sera of patients with systemic lupus erythematosus (SLE), demonstrated additional reactivity with neurons. The neuronal reactivity was greater with cortical neurons than with cerebellar and caudate nucleus neurons, was predominantly IgG, and was immunologically specific. Selected sera from 22 patients with active SLE were tested for the presence of antineuronal antibody. Eleven of 12 sera obtained from patients with neuropsychiatric disease demonstrated definite neuron reactivity, in contrast to only 2 of 10 sera obtained from patients without evidence of neuropsychiatric involvement (P less than 0.005). Five of 21 sera from patients with rheumatoid arthritis, but no sera from 5 other disease control groups, contained antineuronal antibody. Serial studies of 2 SLE patients with transient psychotic episodes demonstrated a close association between antibody titer and the appearance of psychosis in one. These observations suggest that the detection of antineuronal antibodies in patients with SLE may be of value in the diagnosis and management of neuropsychiatric complications.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 371627     DOI: 10.1002/art.1780220401

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  26 in total

Review 1.  Systemic lupus erythematosus: RNA-protein autoantigens, models of disease heterogeneity, and theories of etiology.

Authors:  J B Harley; R H Scofield
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

2.  Neuropsychiatric manifestations of systemic lupus erythematosus: the value of anticardiolipin, antigangliosides and antigalactocerebrosides antibodies.

Authors:  L T Costallat; R M de Oliveira; M B Santiago; W Cossermelli; A M Samara
Journal:  Clin Rheumatol       Date:  1990-12       Impact factor: 2.980

3.  Binding of a monoclonal anti-DNA autoantibody to identical protein(s) present at the surface of several human cell types involved in lupus pathogenesis.

Authors:  L Jacob; M A Lety; D Louvard; J F Bach
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

Review 4.  Immunopathogenesis of the neuropsychiatric manifestations of systemic lupus erythematosus.

Authors:  H G Bluestein; K D Pischel; V L Woods
Journal:  Springer Semin Immunopathol       Date:  1986

5.  Brain Atrophy, Anti-Smooth Muscle Antibody and Cognitive Impairment: An Association Study.

Authors:  Paroni Giulia; Lauriola Michele; Fontana Andrea; D'Onofrio Grazia; Ciccone Filomena; Paris Francesco; Cascavilla Leandro; Urbano Maria; Gravina Carolina; Copetti Massimiliano; Greco Antonio
Journal:  Aging Dis       Date:  2015-11-24       Impact factor: 6.745

6.  Antibodies to protein P in systemic lupus erythematosus.

Authors:  L S Teh; A E Bedwell; D A Isenberg; C Gordon; P Emery; P J Charles; M Harper; N Amos; B D Williams
Journal:  Ann Rheum Dis       Date:  1992-04       Impact factor: 19.103

7.  The neuropsychiatric disorder in systemic lupus erythematosus: evidence for both vascular and immune mechanisms.

Authors:  B Bresnihan; R Hohmeister; J Cutting; R L Travers; M Waldburger; C Black; T Jones; G R Hughes
Journal:  Ann Rheum Dis       Date:  1979-08       Impact factor: 19.103

8.  Stroke as an early manifestation of systemic lupus erythematosus.

Authors:  L F Haas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-06       Impact factor: 10.154

9.  Failure to detect brain reactivity of lymphocytotoxins in cerebral lupus.

Authors:  B A Pussell; F Blyth; J A Charlesworth
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

10.  Serum lymphocytotoxic antibodies and neurocognitive function in systemic lupus erythematosus.

Authors:  A A Long; S D Denburg; R M Carbotte; D P Singal; J A Denburg
Journal:  Ann Rheum Dis       Date:  1990-04       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.